We all know that cancer is a disease that comes in many forms and can turn a patients life upside down. There are a few words that you hope you never have to hear, the words of a doctor thelling you, you have cancer. However, should those words enter your life, it is important to understand that you do have options. One of those options is to become involved with your treatment. One of the easiest ways to do that is to visit Cancer Treatment Centers of America.
One of the first thing you will want to do if you or someone you know has cancer is to learn more about it. Cancer Treatment Centers of America makes education part of the healing process. They talk openly and honestly about cancer and the treatment options. Everything from diagnosis to treatment to survivorship and even caregiver information is talked about. Treatment is started by treating the disease with the latest options like chemotherapy and radiation to name a few. Next they help to manage pain and side effects. The Cancer Treatment Centers of America also offer support for the body and mind. By keeping the quality of life and spirits high they help the patient to become more receptive to treatment options. Think of it like comprehensive care under on umbrella. A treatment center that helps to offer empowering choices about treatment.
Cancer comes in many forms and strikes many areas of the body. You can find it in the lungs, colon, breast, skin, prostate just to name a few areas. Because cancer can be found in many areas of the body, there are no two types of cancer that are alike and as a result, each treatment is unique to each patient. At Cancer Treatment Centers of America they take the time to treat the total patient and the cancer by providing treatment options and cancer specialists that are well respected in their field, and follow their Twitter.
The Cancer Treatment Centers of America (CTCA) isn’t alone in the fight against cancer. CTCA have joined forces with Allscripts and NantHealth to ensure a smooth process that helps doctors overwhelmed by new data when caring for a patient. The use of eviti, a clinical decision support solution allows this to happen.This partnership also allows CTCA to reduce inconsistencies in care. Clinical Pathways enable a greater chance of patients being matched with the proper cancer treatment for their specific diagnosis. Patients can also be approved by insurance providers at a faster rate thanks to accurate data.
While news of CTCA, Allscripts and NantHealth partnering up broke earlier this year, it had been discussed for a little while. Talks began in early 2016 when a need to push an integrated solution forward became apparent. The Chief Executive Officer of Allscripts, Paul Black said CTCA provides “quality care” to its patients. Senior Executive Director of Medical Affairs of NantHealth, Bobby Reddy also praised Cancer Treatment Centers of America and said he was more than happy to work with the network. Under the CTCA are five hospitals with an emphasis on serving cancer patients.
These hospitals are located in the following areas: Philadelphia, Pennsylvania, Tulsa, Oklahoma, and near Atlanta, Georgia; Chicago, Illinois; and Phoenix, Arizona. The network has been serving patients since 1988. Richard J. Stephenson is an investment banker who founded CTCA. He first graduated from Wabash College. He then took his education a step further, graduating from the Northwestern University School of Law. Stephenson founded CTCA when his mother died of bladder cancer. Today, CTCA prides itself on ensuring that only treatment backed by evidence of its effectiveness is used on its patients.
Jason Hope is challenging the current security measures in place around digital currency and IOT devices. IOT, or internet of things, devices are those that are connected to a network of physical devices enabling them to communicate data to one another. This is a very important subject for a lot of individuals, considering how saturated modern culture is with IOT enabled cars, electronics, appliances, and software. Recently, Hope wrote an article for dailyforexreport.com detailing the glaring problems that exist in the security measures around digital currency and IOT devices. Specifically, Hope sights the recent increase in attacks carried out by botnets. These botnets are added to IOT and currency networks in the hopes that they will carry out malicious attacks, rendering the networks useless and obtaining secure data. Hope explains that the small size often necessitated by IoT devices is also a weakness that hackers exploit to gain access to sensitive information. There simply is not enough room for these small devices to put in the required security features mandated by a device carrying such sensitive information. Considering this, Hope explains that more attention should be paid to securing internet of things and digital currency networks against future attacks because as they continue to rise in popularity they will only become more vulnerable.
Hope can speak knowledgeably on the matter of technological security because of his extensive business background and continued philanthropy in the technological field. Hope obtained his B.S in Finance and his MBA from Arizona State University, building the foundation for his business knowledge. He used that and the experience he gained in his field to eventually found his own company. As his success increased, Hope saw the potential to invest in other projects and his company became the parent company for countless other endeavors. Vocationally, Hope is constantly working on ways to contribute to the technological field in relevant ways, and learn more about Jason Hope.
As previously stated, Hope is a committed philanthropist to the technological field. In fact, after a substantial donation to the Strategies for Engineered Negligible Senescence plan the organization was able to make great strides in aging and medical research. Hope also funds a grant program helping young entrepreneurs. He never discounts the help that only $500 can do for someone that is struggling to get a foothold in the business community. Clearly, Hope has seen a need in the world and has used his resources to try and address it in a meaningful way, and https://medium.com/@jasonhope.
The drug is actually in a phase 3 trial against Hodgkin lymphoma, which means it is the first drug used against newly diagnosed or untreated lymphoma. The drug’s goal is to fight lymphoma. In the US and Canada, the drug earned close to 226 million dollars. The company’s partner, Takeda Pharmaceutical, sells the drugs in markets outside the US and Canada.
Adcetris is merely one of over a dozen drugs the company has in research. They want to take another drug, 33A, to phase 3 trials as well. This drug is used to trat acute myeloid leukemia. The company is working on another breast cancer drug and two bladder cancer drugs.
The company, which currently has 800 employee, is looking to hire 100 in the US over the next 5 years, and 20 in Switzerland. These new hires will be focused in the operations department, not research. Siegall, the company CEO, has very ambitious goals. He has said they have room for over 350 employees, but they will focus on 100 for now.
Cancer is one of the deadliest diseases that people find themselves suffering. For one thing, there are many different types of cancer that people can find themselves suffering from. Many of them can be shared by all groups of people. Then there are some that are specific to the gender. As of right now, a lot of research is being done on the devastating disease in order to come up with more effective treatment. While chemotherapy and other established forms of treatment have been successful in treating different forms of cancer, there is still room for improvement when it comes to finding treatment that has fewer side effects.
Among the companies that is working on cancer research is Seattle Genetics. The president and CEO of the company is Dr. Clay B Siegall. He is also involved in Ultrgenix. His work in both companies has a lot to do with biotechnology. The purpose of his research is to come up with effective treatments for disease and treatments that are not easy to cure or treat. For instance, the different forms of cancer are in need of better treatment. One thing that Dr. Clay is well versed in is genetics.
Dr. Clay Siegell is focusing his training and research on targeted cancer therapies. One of the hopes for people who are involved in this type of research is that they come up with something that is effective enough to treat cancer with very few side effects. Often times, cancer happens to go undetected until it is well advanced due to the technological limitations when it comes to detecting cancer. Dr. Clay Siegell and Seattle Genetics is working on bringing forth solutions to this issue so that more people can overcome cancer.
Dr. Clay Siegall has been appointed to the Board of Directors of Mirna Therapeutics, a biotech firm based in Austin, Texas. Dr. Clay Siegall, the CEO of Seattle Genetics, will serve as an outside director on the board. In addition, Dr. Siegall serves on the board of Alder BioPharmaceuticals. Mirna, which specializes in microRNA-based therapeutics in cancer research, has an extensive portfolio of potential products.
MicroRNAs (or MiRNAs) are chains of 20-25 nucleotides that alter gene expression through their interaction with messenger RNA. MiRNAs account for 2% of all mammalian genetics. Dysfunction in normal MiRNA processes is a major factor in the development of cancer, and therapy which replaces dysregulated RNAs has shown enormous potential in cancer treatment.
Dr. Siegall founded Seattle Genetics to explore antibody therapies in cancer treatment. Their main product, ADCETRIS, was approved by the FDA in 2011, and has already gained approval in over 60 countries. In addition, the company has raised over $657 million in financing since its original IPO. Seattle Genetics focuses on Antibody Drug Coagulates (ADCs), and under Dr. Siegall’s leadership, major pharmaceutical companies have licensed Seattle Genetics’ technology. Licensees include Roche, GlaxoSmithKline, and Pfizer.
Dr. Siegall was formerly a researcher at Bristol-Myers Squibb as well as the National Cancer Institute and the National Institutes of Health. He holds a degree in Zoology from the University of Maryland and a PhD in Genetics from George Washington University in Washington, DC. He has over 70 publications to his name as a scientific researcher.